{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:16:56Z","timestamp":1790979416239,"version":"4.1.0"},"posted":{"date-parts":[[2020,8,11]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":62,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mucosal immunity, including secretory IgA (sIgA), plays an important role in early defenses against respiratory pathogens. Salivary testing, the most convenient way to measure sIgA, has been used to characterize mucosal immune responses to many viral infections including SARS, MERS, influenza, HIV, and RSV. However, its role has not yet been characterized in the COVID-19 pandemic. Here, we report development and validation of a rapid immunoassay for measuring salivary IgA against the SARS-CoV-2 virus, and report quantitative results in both pre-COVID-19 and muco-converted subjects.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We developed and refined a specific test for salivary IgA against SARS-CoV-2 on the Brevitest platform, a rapid immunoassay system designed for point-of-care use. A qualitative test was validated as per FDA guidelines with saliva obtained from subjects prior to the emergence of COVID-19, and from PCR-confirmed COVID-19 patients. We also generated a quantitative measure of anti-SARS-CoV-2 salivary IgA. Time taken for saliva self-collection was measured and its ease-of-use assessed.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We successfully validated a qualitative salivary assay for SARS-CoV-2 IgA antibodies, with positive and negative predictive values of 92% and 97%, respectively, and no observable cross-reactivity with any of seven potential confounders. Pre-COVID-19 saliva samples showed an 8-fold range of IgA concentrations, suggesting a broad continuum of natural antibody resistance against the novel virus, though at levels lower than that observed in COVID-19 PCR-confirmed subjects. Samples from muco-positive subjects also shown a ~9-fold variation in salivary IgA levels, with elevated salivary IgA observed beyond three months after onset of symptoms. We observed a correlation (r=0.4405) between salivary IgA levels and COVID-19 disease severity. In anecdotal observations, we observed individuals who exhibited antibodies early in the course of their disease, contemporaneously with a positive PCR test, as well as individuals who muco-converted despite no known direct exposure to a COVID-19 patient, no symptoms, and negative molecular and\/or serum antibody tests. Salivary collection took 5-10 minutes, and was reported as being easy (mean of 1.1 on a scale of 1 to 10).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Implications<\/jats:title>\n                  <jats:p>Mucosal immunity, including secretory IgA, plays an important role in host defense against respiratory pathogens, and our early data suggest it may do so in COVID-19. Salivary IgA, an accessible marker of mucosal immunity, may be a useful indicator of several key parameters including individual and community immune response, disease severity, clinical risk, and herd immunity. The non-invasive nature and ease of saliva collection facilitates its potential use as a biomarker for ongoing patient assessment and management, as well as a community surveillance tool. By measuring mucosal immune responses directly and systemic immune responses indirectly, salivary IgA could be useful in developing and deploying a vaccine(s) against COVID-19. Quantitative IgA assessment could also potentially serve as a tool to segment the population into different risk categories and inform individual and collective decisions relating to appropriate activities and vaccine prioritization\/delivery. These data reinforce the importance of further investigation into the role of mucosal immunity and IgA in host responses against COVID-19.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2020.08.07.20170258","type":"posted-content","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T18:40:53Z","timestamp":1597171253000},"source":"Crossref","is-referenced-by-count":64,"title":["Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-3283","authenticated-orcid":false,"given":"Atul","family":"Varadhachary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Patrick","family":"Garr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Letkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Breeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbyn","family":"Traylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Leo","family":"Linbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2021012901550645000_2020.08.07.20170258v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"2021012901550645000_2020.08.07.20170258v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30845-X"},{"key":"2021012901550645000_2020.08.07.20170258v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"issue":"22","key":"2021012901550645000_2020.08.07.20170258v1.4","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMe2009758","article-title":"Asymptomatic transmission, the Achilles\u2019 heel of current strategies to control COVID-19","volume":"382","year":"2020","journal-title":"N Engl J Med"},{"key":"2021012901550645000_2020.08.07.20170258v1.5","unstructured":"World Health Organization (2020a). Coronavirus disease (COVID-19-2019) situation reports. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\/"},{"key":"2021012901550645000_2020.08.07.20170258v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2009324"},{"key":"2021012901550645000_2020.08.07.20170258v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-00240-0"},{"key":"2021012901550645000_2020.08.07.20170258v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"2021012901550645000_2020.08.07.20170258v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.04.002"},{"key":"2021012901550645000_2020.08.07.20170258v1.10","first-page":"30200","article-title":"Clinical and virological data of the first cases of COVID-19 in Europe: a case series","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021012901550645000_2020.08.07.20170258v1.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01237.x"},{"key":"2021012901550645000_2020.08.07.20170258v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.71"},{"key":"2021012901550645000_2020.08.07.20170258v1.13","first-page":"e00696","article-title":"Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against viral infections","volume":"9","year":"2018","journal-title":"mBio"},{"key":"2021012901550645000_2020.08.07.20170258v1.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030596"},{"key":"2021012901550645000_2020.08.07.20170258v1.15","doi-asserted-by":"crossref","unstructured":"Secretory immunity with special reference to the oral cavity. Brandtzaeg P . J Oral Microbiol. 2013; 5.","DOI":"10.3402\/jom.v5i0.20401"},{"key":"2021012901550645000_2020.08.07.20170258v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90146-C"},{"key":"2021012901550645000_2020.08.07.20170258v1.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-6-892"},{"key":"2021012901550645000_2020.08.07.20170258v1.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00228801"},{"key":"2021012901550645000_2020.08.07.20170258v1.19","doi-asserted-by":"crossref","first-page":"11816","DOI":"10.1016\/S0021-9258(18)33837-7","article-title":"A transmembrane precursor of secretory component, the receptor for transcellular transport of secretory immunoglobulins","volume":"257","year":"1982","journal-title":"J Biol Chem"},{"key":"2021012901550645000_2020.08.07.20170258v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/255745a0"},{"key":"2021012901550645000_2020.08.07.20170258v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"2021012901550645000_2020.08.07.20170258v1.22","first-page":"773775","article-title":"Serum IgA, IgM, and IgG responses in COVID-19","volume":"17","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"2021012901550645000_2020.08.07.20170258v1.23","doi-asserted-by":"crossref","unstructured":"Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Yu H , et al. European Respiratory Journal. Jan 2020, 2001526.","DOI":"10.1183\/13993003.01526-2020"},{"key":"2021012901550645000_2020.08.07.20170258v1.24","unstructured":"Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection. Faustini SE , et al. Version 1. medRxiv. Preprint. 2020 Jun 18."},{"key":"2021012901550645000_2020.08.07.20170258v1.25","unstructured":"COVID-19 Serology at population scale: SARS-CoV-2-specific antibody responses in saliva. Randad PR , et al. medRxiv. 2020 May 26; 2020.05.24"},{"issue":"1","key":"2021012901550645000_2020.08.07.20170258v1.26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0300-9785(86)80014-X","article-title":"The concentration of salivary IgA in whole and parotid saliva and the effect of stimulation","volume":"15","year":"1986","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2021012901550645000_2020.08.07.20170258v1.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03545.x"},{"key":"2021012901550645000_2020.08.07.20170258v1.28","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2019.01787","article-title":"Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination","volume":"10","year":"2019","journal-title":"Front. Immunol"},{"key":"2021012901550645000_2020.08.07.20170258v1.29","unstructured":"SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals. Hansen CB , et al. BioRxiv. Preprint. 2020, July 29."},{"key":"2021012901550645000_2020.08.07.20170258v1.30","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2008-0260OC"},{"issue":"10","key":"2021012901550645000_2020.08.07.20170258v1.31","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1128\/IAI.65.10.3997-4004.1997","article-title":"Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans","volume":"65","year":"1997","journal-title":"Infect Immun"},{"key":"2021012901550645000_2020.08.07.20170258v1.32","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.1.1-4.1998"},{"key":"2021012901550645000_2020.08.07.20170258v1.33"},{"key":"2021012901550645000_2020.08.07.20170258v1.34","unstructured":"Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in Covid-19-naive individuals. Egia-Mendikute L , et al. MediRxiv pre-print July 29, 2020."},{"key":"2021012901550645000_2020.08.07.20170258v1.35","unstructured":"Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. Ng KW , et al. MediRxiv pre-print July 23, 2020."},{"key":"2021012901550645000_2020.08.07.20170258v1.36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2018.0614"},{"issue":"7","key":"2021012901550645000_2020.08.07.20170258v1.37","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1249\/MSS.0b013e31816be9c3","article-title":"Salivary IgA as a risk factor for upper respiratory infections in elite professional athletes","volume":"40","year":"2008","journal-title":"Medicine & Science in Sports & Exercise"},{"issue":"1","key":"2021012901550645000_2020.08.07.20170258v1.38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1399-3038.1994.tb00218.x","article-title":"Salivary anti-RSV IgA antibodies and respiratory infections during the first year of life in atopic and non-atopic infants","volume":"5","year":"1994","journal-title":"Pediatr. Allergy Immunol"},{"key":"2021012901550645000_2020.08.07.20170258v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(97)00002-0"},{"key":"2021012901550645000_2020.08.07.20170258v1.40","doi-asserted-by":"publisher","DOI":"10.1097\/00004703-199610000-00004"},{"key":"2021012901550645000_2020.08.07.20170258v1.41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-319-20215-0_10","article-title":"Mechanisms of stress-mediated modulation of upper and lower respiratory tract infections","volume":"874","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"2021012901550645000_2020.08.07.20170258v1.42","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-302X.2002.170306.x"},{"key":"2021012901550645000_2020.08.07.20170258v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90325-Y"},{"issue":"1","key":"2021012901550645000_2020.08.07.20170258v1.44","first-page":"1399","article-title":"Changes in the concentration and distribution of immunoglobulin-producing cells in SIDS palatine tonsils","volume":"6","year":"1995","journal-title":"Pediatric Allergy and Immunology"},{"key":"2021012901550645000_2020.08.07.20170258v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsim.2004.06.019"},{"issue":"4","key":"2021012901550645000_2020.08.07.20170258v1.46","first-page":"423","article-title":"Structure and function of human IgA Fc receptors (Fc alpha R)","volume":"16","year":"1996","journal-title":"Crit Rev Immunol"},{"key":"2021012901550645000_2020.08.07.20170258v1.47","unstructured":"Identification of novel mechanistically distinct endotypes of pandemic influenza-associated acute respiratory failure. Samanta R , et al. MediRxiv pre-print July 14, 2020."},{"key":"2021012901550645000_2020.08.07.20170258v1.48","unstructured":"Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Aschenbrenner AC , et al. MediRxiv pre-print July 14, 2020."},{"key":"2021012901550645000_2020.08.07.20170258v1.49","unstructured":"Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. Shi H , et al. MediRxiv pre-print July 15, 2020."},{"key":"2021012901550645000_2020.08.07.20170258v1.50","unstructured":"COVID-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. Mahase E . BMJ. 2020; 369."},{"key":"2021012901550645000_2020.08.07.20170258v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.023"},{"key":"2021012901550645000_2020.08.07.20170258v1.52","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25685"},{"issue":"2","key":"2021012901550645000_2020.08.07.20170258v1.53","doi-asserted-by":"crossref","first-page":"e19054","DOI":"10.2196\/19054","article-title":"Detection of SARS-CoV-2 RNA and antibodies in diverse samples: protocol to validate the sufficiency of provider-observed, home-collected blood, saliva, and oropharyngeal samples","volume":"6","year":"2020","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"2021012901550645000_2020.08.07.20170258v1.54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/infdis\/jiz321","article-title":"Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction","volume":"221","year":"2020","journal-title":"J Infect Dis"},{"key":"2021012901550645000_2020.08.07.20170258v1.55","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw230"},{"issue":"42","key":"2021012901550645000_2020.08.07.20170258v1.56","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1016\/j.vaccine.2014.07.078","article-title":"Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"2021012901550645000_2020.08.07.20170258v1.57","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00016-T"},{"key":"2021012901550645000_2020.08.07.20170258v1.58","doi-asserted-by":"publisher","DOI":"10.1086\/425517"},{"key":"2021012901550645000_2020.08.07.20170258v1.59","doi-asserted-by":"publisher","DOI":"10.1086\/590669"},{"issue":"44-46","key":"2021012901550645000_2020.08.07.20170258v1.60","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1016\/j.vaccine.2006.05.041","article-title":"The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man","volume":"24","year":"2006","journal-title":"Vaccine"},{"key":"2021012901550645000_2020.08.07.20170258v1.61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.17.7956-7965.2001"},{"key":"2021012901550645000_2020.08.07.20170258v1.62","doi-asserted-by":"crossref","unstructured":"Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 Vector Prime, Env Protein boost immunizations in Rhesus monkeys. Kang ZH , et al. Journal of Virology. Jul 2018; 92 (15).","DOI":"10.1128\/JVI.00537-18"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.08.07.20170258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:50:53Z","timestamp":1768485053000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.08.07.20170258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1101\/2020.08.07.20170258","relation":{},"subject":[],"published":{"date-parts":[[2020,8,11]]},"subtype":"preprint"}}